What is the half-life of Eliquis (apixaban)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Half-Life of Eliquis (Apixaban)

The half-life of Eliquis (apixaban) is approximately 12 hours in healthy individuals, but can range from 8-15 hours depending on patient factors. 1

Detailed Information on Apixaban Half-Life

Apixaban demonstrates consistent pharmacokinetics with the following characteristics:

  • Standard half-life: Approximately 12 hours in healthy individuals 2, 1
  • Terminal elimination half-life: After oral administration, apixaban has an apparent half-life of approximately 12 hours 2
  • Absorption: Rapidly absorbed with maximum concentration occurring 3-4 hours after oral administration 1
  • Bioavailability: Approximately 50% for doses up to 10 mg 2

Factors Affecting Apixaban Half-Life

The half-life of apixaban can be significantly affected by several patient-specific factors:

Renal Function

Half-life varies based on creatinine clearance (CrCl) 3:

  • Normal renal function (CrCl ≥80 mL/min): 6-15 hours
  • Mild impairment (CrCl 50-79 mL/min): 6-15 hours
  • Moderate impairment (CrCl 30-49 mL/min): 6-15 hours
  • Severe impairment (CrCl 15-29 mL/min): 17 hours
  • End-stage renal disease (CrCl <15 mL/min): 17 hours (off dialysis)

Age

  • Older patients (>75 years): Half-life extends to 11-13 hours 3

Hepatic Function

  • Mild to moderate hepatic impairment: Similar pharmacokinetics to healthy subjects, but caution is advised 2
  • Severe hepatic impairment: Not well studied and generally contraindicated 4

Elimination Pathway

Apixaban has multiple elimination pathways 2, 1:

  • Renal excretion: Approximately 27% of total clearance
  • Hepatic metabolism: Primarily via CYP3A4 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2
  • Biliary excretion and direct intestinal excretion account for the remainder

Clinical Implications of Apixaban's Half-Life

The 12-hour half-life of apixaban has important clinical implications:

  1. Dosing frequency: The half-life supports twice-daily dosing regimen 4

  2. Perioperative management:

    • For procedures with low bleeding risk: Discontinue apixaban at least 24 hours before (2 half-lives)
    • For procedures with high bleeding risk: Discontinue apixaban at least 48 hours before (4 half-lives) 3
  3. Overdose management: In case of overdose, the anticoagulant effect can be expected to persist for at least 24 hours (approximately 2 drug half-lives) 2, 5

  4. Drug interactions: Strong inhibitors of both CYP3A4 and P-glycoprotein can significantly increase apixaban plasma concentrations and effectively prolong its half-life 2

Important Considerations

  • Hemodialysis: Has minimal impact on apixaban exposure due to high protein binding (87%) 2
  • Reversal agents: Andexanet alfa is available as a specific reversal agent for factor Xa inhibitors including apixaban 2
  • Monitoring: Unlike warfarin, routine coagulation monitoring is not required for apixaban 4

The predictable half-life and pharmacokinetics of apixaban allow for reliable anticoagulation in most patients, with dosing adjustments primarily needed for patients with specific risk factors such as renal impairment, advanced age, or low body weight.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Anticoagulation Therapy with Apixaban

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.